WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Three-Pronged attack on rare blood cancer enters human testing
Disease control Not yet recruitingThis study is testing a new three-drug combination for people newly diagnosed with Waldenstrom's macroglobulinemia, a rare blood cancer. It will see if adding a new drug called nemtabrutinib to two existing drugs (bortezomib and rituximab) is safe and effective at controlling the…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New pill combo aims to control rare blood cancer
Disease control Not yet recruitingThis study is testing whether a combination of two oral drugs, zanubrutinib and BGB-11417, can effectively control a rare blood cancer called Waldenström's macroglobulinemia in patients whose disease has returned after prior treatment. The goal is to see if this limited-duration …
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Experimental drug targets tough blood cancers in early safety trial
Disease control Not yet recruitingThis early-stage trial is testing a new drug called LY4152199 in people with B-cell lymphomas that have returned or didn't respond to previous treatments. The main goals are to find a safe dose and see if the drug shows any signs of helping control the cancer. The study will enro…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC